Medical Device
Manufacturing
THE TRADE PAPER OF THE FACTORY FLOOR
Z-0567-2022Class II

THERAKOS CELLEX Photopheresis Procedural Kit, CLXUSA

Mallinckrodt Pharmaceuticals Ireland Ltd / initiated 2021-12-10 / Open, Classified / root cause: sterility

Mallinckrodt Pharmaceuticals Ireland Ltd began a recall of THERAKOS CELLEX Photopheresis Procedural Kit, CLXUSA on . FDA classified it as Class II and gives the reason as "This recall was initiated to recover a Dunnage Case, which is a case of three (3) CLXUSA kits. This Dunnage Case was shipped on 02-Dec-2021. Dunnage is used during the sterilization process and is not intended for...". As of , the recall status on record is Open, Classified, and MDM tags the root cause as sterility.

Recall record

Recall number
Z-0567-2022
Classification
Class II
Status
Open, Classified
Initiated
Posted
Recalling firm
Mallinckrodt Pharmaceuticals Ireland Ltd
Product
THERAKOS CELLEX Photopheresis Procedural Kit, CLXUSA
Product code
LNR System, Photopheresis, Extracorporeal
Reason for recall
This recall was initiated to recover a Dunnage Case, which is a case of three (3) CLXUSA kits. This Dunnage Case was shipped on 02-Dec-2021. Dunnage is used during the sterilization process and is not intended for customer use.
Root cause tag
sterility
FDA root cause
Under Investigation by firm
Action
On December 10, 2021, the firm initiated phone calls to potentially affected customers. The firm identified the location of the Dunnage Case on the same day, and the Dunnage Case was returned to the recalling firm.
Quantity in commerce
3
Distribution
US Nationwide distribution in the states of CA, FL, GA, MA, MI, NC, NJ, NY, OH, TN, TX, VA, WV.
Product codes and lots
Dunnage case consists of a random unknown lot, which may have been shipped in place of Kit lot K341

Enforcement reports

One row per recalled product line
FDA enforcement reports joined to recall event Z-0567-2022
Recall numberClassStatusVoluntary or mandatedReport dateClassified
Z-0567-2022Class IIOngoingVoluntary: Firm initiated